Navigation Links
Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns


Introduction
While full coverage C18 phases have been responsible for the growth of HPLC as a reliable high efficiency technique, it has become apparent in recent years that such column types are not suited for reliable analysis of highly polar compounds under low organic or aqueous mobile phase conditions. It was shown that by incorporating a polar group in the alkyl bonded phase reagent extra retention could be obtained for polar solutes while maintaining the operating characteristics of traditional reversed phase columns. Adding polarity to the bonded alkyl phase also overcame 'bonded phase collapse', the steady decline of retention times under (near) aqueous mobile phase conditions. In this note we report on an alternative method to obtain enhanced retention of polar solutes by creating a low density bonded phase that is fully accessible to water molecules.


Results
TSK-GEL ODS-100V columns contain high purity five micron silica particles with 100 angstrom pores and 450m2/g surface area, which are functionalized by an incomplete reaction with a difunctional octadecylsilane reagent (see Figure 1 ). The low density C18 monolayer is then endcapped with two difunctional dialkylsilane reagents to improve the peak shape of basic compounds, while maintaining stable analysis times in low organic or aqueous mobile phases.


To demonstrate the absence of accessible silanol groups, Figure 2 compares retention and peak shape for two tricyclic antidepressant drugs on four commercial water-wettable columns.


The same commercial columns were also evaluated wi th organic acids under low pH conditions in 2% acetonitrile, as is shown in Figure 3 .



Conclusion
The ability to provide symmetrical peak shapes for basic as well as acidic compounds make TSKgel ODS-100V the column of choice for method development and quantitative analysis of small molecular weight compounds.


Ordering Information


More Infomation
TSKgel ODS-100V



'"/>

Source:


Page: All 1 2

Related biology technology :

1. Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase
2. High-Fidelity PCR with a Novel Polymerase Mixture
3. Challenge the Performance of Your Hot-Start PCRs with FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System
4. Combine High Yield, Great Accuracy and the Prevention of Carry-over Contamination by Using the Novel Expand High FidelityPLUS PCR System
5. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
6. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
7. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
8. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
9. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
10. Enhanced PCR Cloning System
11. Enhanced Amplification of Long Targets with PfuTurbo DNA Polymerase
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):